TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025 ...

RevolKa will create and deliver highly functional proteins, in collaboration with Daiichi Sankyo Co., Ltd. by using its proprietary protein engineering platform technology, called aiProtein®: a ...

Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer ... its President and Chief Operating Officer Hiroyuki Okuzawa told Bloomberg News on Friday in ...

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ETCompany Participants. Hiroyuki Okuzawa - Representative Director, President & Chief ...